Starpharma Holdings

Starpharma Holdings Quick Ratio

The Quick Ratio (Acid Test) of Starpharma Holdings (SPL.AX) as of Nov 10, 2026 is 2.28. In the previous year, Quick Ratio (Acid Test) was 2.47 — a change of -7.64% (lower).

Quick Ratio

2.28

YoY

-7.64%

Last updated:

Quick Ratio (Acid Test) of Starpharma Holdings is 2026 2.28 . Quick Ratio (Acid Test) of Starpharma Holdings was 2025 2.47 . It decreases by -7.64% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Starpharma Holdings Stock analysis

What does Starpharma Holdings do? Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starpharma Holdings stock

Quick Ratio (Acid Test) of Starpharma Holdings is 2.28 in 2026.

Quick Ratio (Acid Test) of Starpharma Holdings changed from 2.47 to 2.28, representing a -7.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Starpharma Holdings since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Starpharma Holdings with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Starpharma Holdings

All Key Metrics — Starpharma Holdings